Revenue: As of FY2026 Q2, the actual value is USD 10.88 M, missing the estimate of USD 12.73 M.

EPS: As of FY2026 Q2, the actual value is USD -0.38, missing the estimate of USD -0.2867.

EBIT: As of FY2026 Q2, the actual value is USD -9.962 M.

Second Quarter 2026 Financial Highlights

Total Revenue

ClearPoint Neuro, Inc. reported total revenue of $10.9 million for the three months ended June 30, 2026, an 18% increase from $9.2 million for the same period in 2025. For the six months ended June 30, 2026, total revenue was $23.0 million, up from $17.7 million for the six months ended June 30, 2025.

Segment Revenue

• Biologics and Drug Delivery Revenue: This segment’s revenue decreased to $4.0 million for the three months ended June 30, 2026, from $4.7 million in the prior year, representing a 15% decline primarily due to a non-recurring customer order. Growth in preclinical service revenue partially offset this decline, and the segment is expected to return to growth in the third quarter.
• Neurosurgery Navigation and Therapy Revenue: This segment saw an increase of 62% to $5.6 million for the three months ended June 30, 2026, from $3.4 million in the same period in 2025, driven by IRRAflow product revenues and the introduction of 3.0 operating room navigation software.
• Capital Equipment and Software Revenue: This segment’s revenue increased by 24% to $1.3 million for the three months ended June 30, 2026, from $1.0 million in the same period in 2025, attributed to increased placements of ClearPoint navigation capital and software, IRRAflow control units, and Prism laser units.

Gross Profit and Margin

Gross profit for the three months ended June 30, 2026, was $6.7 million, compared to $5.6 million for the same period in 2025. The gross margin for the three months ended June 30, 2026, was 62%, up from 60% in the same period in 2025, primarily due to lower excess and obsolete inventory. The gross margin was 63% for the trailing twelve months ended June 30, 2026.

Operating Expenses and Loss

Operating expenses increased by 51% to $17.0 million for the three months ended June 30, 2026, from $11.2 million for the same period in 2025, mainly due to higher personnel, occupancy, and travel costs from the IRRAS acquisition in November 2025. The operating loss for the three months ended June 30, 2026, was - $10.2 million, compared to - $5.7 million for the same period in 2025. For the six months ended June 30, 2026, the operating loss was - $18.7 million, compared to - $11.8 million for the six months ended June 30, 2025.

Net Loss

Net loss for the three months ended June 30, 2026, was - $11.3 million, compared to - $5.8 million for the same period in 2025. For the six months ended June 30, 2026, net loss was - $20.9 million, compared to - $11.9 million for the six months ended June 30, 2025.

Cash and Cash Equivalents

As of June 30, 2026, cash and cash equivalents totaled $29.4 million, a decrease from $45.9 million at December 31, 2025. The decrease resulted from - $15.0 million in cash used for operating activities and - $2.0 million in cash paid for taxes related to net share settlement of equity awards.

Cash Flow from Operating Activities

Net cash used in operating activities was - $15.0 million for the six months ended June 30, 2026, compared to - $8.7 million for the six months ended June 30, 2025.

Cash Flow from Investing Activities

Net cash used in investing activities was - $0.9 million for the six months ended June 30, 2026, compared to - $0.3 million for the six months ended June 30, 2025.

Cash Flow from Financing Activities

Net cash used in financing activities was - $0.8 million for the six months ended June 30, 2026, compared to $30.6 million provided by financing activities for the six months ended June 30, 2025.

Other Financial Metrics

Total assets were $86.7 million at June 30, 2026, down from $97.7 million at December 31, 2025. Total liabilities were $76.0 million at June 30, 2026, up from $69.7 million at December 31, 2025. Total stockholders’ equity was $10.8 million at June 30, 2026, down from $28.0 million at December 31, 2025. ClearPoint Neuro, Inc. reported $37.0 million in revenue for the year ended December 31, 2025. The company has invested over $100 million in capital over the past five years and over $200 million over the past 15 years to build its platform.

Operational Metrics

ClearPoint Neuro, Inc. expects 10-15 clinical trials using its technology to be enrolling patients in the next 18 months, alongside approximately 10 partner clinical trial data readouts. The company has entered into multiple statements of work for preclinical services at its ClearPoint Advanced Laboratories (CAL) facility, including its first GLP services statement of work, expected to be completed in the first half of 2027. ClearPoint Neuro, Inc. also plans to enter the focused ultrasound market through a partnership with the SONOCARE Lab at Sungkyunkwan University, South Korea. The company holds over 130 issued patents and employs more than 160 individuals worldwide. Its installed base has grown to more than 175 active global centers, and its technology has been used in over 10,000 procedures to date. ClearPoint Neuro, Inc. has regulatory approvals in 34 countries, collaborates with over 60 active pharma partners, and has more than 25 active clinical trials involved in over 15 neuro-focused indications. More than 10 of its programs have been accepted for FDA expedited review, and it has one approved combination device. Approximately 50% of the top-ranked neurosurgery programs utilize ClearPoint Neuro, Inc. technology.

Business Outlook and Guidance

ClearPoint Neuro, Inc. estimates its revenue for 2026 to be between $48.0 million and $52.0 million and anticipates that its operational cash burn will decrease in the second half of the year. The company’s ‘Fast. Forward.’ 4-Pillar Growth Strategy aims to capture 20% of an existing $1.0 billion global market opportunity, generating $200 million in annual revenue and achieving cash breakeven and profitability. Furthermore, the ‘Essential. Everywhere.’ 5-Pillar Growth Strategy targets $500 million in revenue by building a new market for cell and gene therapy, enabling 20,000 annual procedures, and generating an additional $300 million annually.